Navigation Links
ULURU Inc. Reports First Quarter 2008 Financial Results
Date:5/12/2008

125,045 213,805

Interest expenses --- (1,574)

(LOSS) BEFORE INCOME TAXES (1,814,659) (847,151)

Income taxes --- ---

NET (LOSS) $(1,814,659) $(847,151)

Basic and diluted net (loss)

per common share $(0.03) $(0.01)

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING 62,429,586 60,729,997

ULURU Inc.

SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATA

March 31, 2008 December 31, 2007

(Unaudited) (Audited)

Cash and cash equivalents $13,171,228 $13,979,828

Current assets 14,550,448 15,536,146

Property and equipment, net 1,883,995 1,532,881

Other assets 10,788,357 11,053,976

Total assets 27,222,800 28,123,003

Current liabilities 1,509,245 1,389,989

Long term liabilities - deferred

revenue 1,035,619 495,281

Total liabilities 2,544,864 1,885,270

Total stockholders' equity 24,677,936 26,237,733

Contact: Company

Kerry P. Gray

President & CEO

Terry K. Wallberg

Vice President & CFO

(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
2. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
4. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. Reports Third Quarter 2007 Results
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
8. ULURU Inc. Announces Odd-Lot Buy Back Offer
9. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
10. Novadaq Reports Financial Results for the First Quarter of 2008
11. Isis Reports Financial Results and Highlights for First Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...disease by 20 years after operation, study says ,...ver transplant patients have a higher incidence of...rs in Finland. , In a new study published in t...rchers investigated the cancer risk pattern in 540... University Central Hospital. The patients were gi...
(Date:10/10/2008)...re/ -- More than 600 new Wisconsin,voters can part...s is the,result of Aurora Health Care,s voter regi...f the health care system,s 13 hospitals across Eas... vote at the drives., Aurora employees and volunt... Accountability Board to serve as special registra...
(Date:10/10/2008)...pletion of a highly successful CIO Finance Summit ...ces their next business technology gathering, and ...ves in healthcare. CDM Media has confirmed the CIO...the Four Seasons Resort in Scottsdale, AZ. , ...1, 2008 -- Upon the completion of a highly success...
(Date:10/10/2008)...10 /PRNewswire/ -- A senior citizen,soared over th... small,plane. The high-flying adventure was taken ...came from a last-wish program through Silverado Ho...where Heden was a patient.,Called Go Wish, the pro...,many realize a special activity at the end of the...
Breaking Medicine News(10 mins):Health News:Liver Transplant Patients at Higher Cancer Risk 2Health News:CIO Healthcare Summit Announces Dates and VIP Delegates 2Health News:Deck of Cards is More Than a Game: Integral in Silverado Hospice Care 2
...n's Hospital is all set to cancel several hundred ...ncellations //of elective surgeries beginning yest...ld mean that up to 1800 patients would be unable t...-month period. The Acting General Manager of the ...
...e, especially decaffeinated could offer protection...The report on the study that was conducted by the ...ve no definite clue as to what might be causing th... it could be possible that minerals and non-nutrit...
... accused the Government; of trying to "privatise t...alled on large private// sector companies to apply...xplaining that the notice on the contract in the O...said, 'The NHS is progressing with the implementat...
...nts of Private Medical and Dental Colleges (AMUPMD...lka Samiti and has decided// that all 29 medical c...e 21, the Shikshan Shulka Samiti has announced a 7... on an ad hoc basis. That meant that medical fees ...
Other Medicine News:Health News:Surgery cancellations in Queens land Hospital 2Health News:Decaffeinated Coffee Might Protect Against Adult Onset Of Diabetes 2Health News:Government Accused Of Yielding NHS To Outside Interests 2
(Date:10/10/2008)...SWARTZ CREEK, Mich., Oct. 10 /- Diplo...euroscience has selected Diplomat,Specialty Pharma... a large,scale, national Therapy Optimization Stud...the two year TOP MS study, is to examine the benef...gram on compliance, adherence and,patient outcomes...
(Date:10/10/2008)...WALTHAM, Mass., Oct. 10 /- ... a leading provider of near-patient,diagnostics, m...terday with,Ban Ki-moon, the Secretary-General of ...xecutives of seventeen of the world,s leading,rese...ic companies.,Inverness, together with senior offi...
(Date:10/10/2008)...PLEASANTON, Calif., Oct. 10 /- TriRem...een authorized to affix the CE (Conformite,Europee...es(TM) Coronary,Stent System, a unique main vessel...r coronary bifurcations., Representing the next g... system has potential use in a quarter of the 2.2 ...
(Date:10/9/2008)...World Sight Day 2008 focuses on the need to protec.../- Of the 45 million people worldwide...ree-quarters of them could,have avoided their blin...ed., To view the Multimedia News Release, go to:,...on, the world,s leader in eye care products and eq...
Breaking Medicine Technology:Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2ORBIS and Alcon Call Attention to the Aging Eye 2ORBIS and Alcon Call Attention to the Aging Eye 3Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio 1287 1Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio 1287 2Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio 1287 3Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio 1287 4XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007 533 1XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007 533 2XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007 533 3 244 million AHRQ grant supports research to improve hospital care 3776 1 244 million AHRQ grant supports research to improve hospital care 3776 2UD named a regional research participant in National Children 26 23146 3Bs Study 819 1UD named a regional research participant in National Children 26 23146 3Bs Study 819 2
...Journal of Clinical Oncology -, NEW YORK, July 06,...se II study - which will be published in the Augus...gy (JCO) and are now,available as an Early Release...co.org/">www.jco.org - demonstrate that,ixabepilo...,compound, has activity in patients with metastati...
...25, an Investigational NNRTI,from Tibotec, YARDLEY...,ongoing Phase 3 studies (DUET-1 and DUET-2) showe...umented non-nucleoside reverse,transcriptase inhib...e reached an undetectable viral load (defined as a...NA copies/mL) with,TMC125 (etravirine), Tibotec,s ...
Other Medicine Technology:Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 2Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 3Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 4TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
...veloped a range of Milli-Q ultrapure water systems...ents. Each of the five new Milli-Q systems is desi...al to particular applications such as HPLC, molecu...high precision resistivity monitor that records co...
...veloped a range of Milli-Q ultrapure water systems...ents. Each of the five new Milli-Q systems is desi...al to particular applications such as HPLC, molecu...high precision resistivity monitor that records co...
Inquire
Adjustable speed vortex with inter-changeable heads, 110 V
Medicine Products: